# KEYTRUDA® (pembrolizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pembrolizumab

> The FDA approved KEYTRUDA® (pembrolizumab), sponsored by Merck & Co., Inc. (MRK), on August 4, 2026 for muscle-invasive bladder cancer.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KEYTRUDA® (pembrolizumab) |
| Codes | MK-4280A, MK-3475, SCH-900475, OT-101 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [advanced or metastatic merkel cell carcinoma](https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma), [recurrent solid tumors](https://sec-api.dev/indications/recurrent-solid-tumors), [muscle-invasive bladder cancer](https://sec-api.dev/indications/muscle-invasive-bladder-cancer), [Urinary Bladder Neoplasms](https://sec-api.dev/indications/urinary-bladder-neoplasms), [Urinary Bladder Cancer, Muscle-invasive](https://sec-api.dev/indications/urinary-bladder-cancer-muscle-invasive), [Breast Neoplasms](https://sec-api.dev/indications/breast-neoplasms), Advanced Cancer, [High-risk Non-muscle Invasive Bladder Cancer](https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer) |
| Modality | antibody |
| FDA designations | fast track, priority review |

## Timeline

### January 8, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-66 (Efficacy): submission_status AP, submission_status_date 20200108, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### April 28, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-80 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-64 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-62 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-60 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-79 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-77 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-69 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-83 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-81 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-59 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-63 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-61 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-78 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-76 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-82 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### June 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-71 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-90 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-92 (Efficacy): submission_status AP, submission_status_date 20200624, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-68 (Efficacy): submission_status AP, submission_status_date 20200624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### June 29, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-84 (Efficacy): submission_status AP, submission_status_date 20200629, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 2, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 14, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-85 (Efficacy): submission_status AP, submission_status_date 20201014, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### November 13, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-88 (Efficacy): submission_status AP, submission_status_date 20201113, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### March 16, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-93 (Efficacy): submission_status AP, submission_status_date 20210316, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20210316, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-96 (Efficacy): submission_status AP, submission_status_date 20210322, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### May 5, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20210505, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### July 1, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-100 (Efficacy): submission_status AP, submission_status_date 20210701, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### July 21, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-105 (Efficacy): submission_status AP, submission_status_date 20210721, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-114 (Efficacy): submission_status AP, submission_status_date 20210726, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-89 (Efficacy): submission_status AP, submission_status_date 20210726, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### August 10, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-102 (Efficacy): submission_status AP, submission_status_date 20210810, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### August 31, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-118 (Efficacy): submission_status AP, submission_status_date 20210831, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-117 (Efficacy): submission_status AP, submission_status_date 20210831, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 13, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20211013, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-121 (Efficacy): submission_status AP, submission_status_date 20211013, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### November 17, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-113 (Efficacy): submission_status AP, submission_status_date 20211117, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### December 3, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20211203, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### December 17, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-120 (Efficacy): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### February 4, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-95 (Efficacy): submission_status AP, submission_status_date 20220204, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### March 21, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-110 (Efficacy): submission_status AP, submission_status_date 20220321, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### May 20, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-123 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### December 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-127 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### January 26, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-128 (Efficacy): submission_status AP, submission_status_date 20230126, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### March 28, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20230328, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-136 (Efficacy): submission_status AP, submission_status_date 20230403, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### August 14, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-134 (Efficacy): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 12, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-138 (Efficacy): submission_status AP, submission_status_date 20231012, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-139 (Efficacy): submission_status AP, submission_status_date 20231016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 23, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-142 (Efficacy): submission_status AP, submission_status_date 20231023, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-145 (Efficacy): submission_status AP, submission_status_date 20231031, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-144 (Efficacy): submission_status AP, submission_status_date 20231031, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### November 7, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-148 (Efficacy): submission_status AP, submission_status_date 20231107, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-143 (Efficacy): submission_status AP, submission_status_date 20231116, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### December 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-151 (Efficacy): submission_status AP, submission_status_date 20231215, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-152 (Efficacy): submission_status AP, submission_status_date 20231215, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### January 12, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-147 (Efficacy): submission_status AP, submission_status_date 20240112, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### January 25, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-124 (Efficacy): submission_status AP, submission_status_date 20240125, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-21, last confirmed 2025-02-21.
- SEC Form 10-K (accession 0001682852-25-000022): "Following results of the Phase 1b study, we began enrollment of the Phase 2 portion of the study in June 2024." https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm

### June 7, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-154 (Efficacy): submission_status AP, submission_status_date 20240607, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-155 (Efficacy): submission_status AP, submission_status_date 20240617, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### August 7, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-157 (Efficacy): submission_status AP, submission_status_date 20240807, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### September 17, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-161 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### September 26, 2024: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss the existing supplemental biologics license applications (sBLA) which were approved for patients with previously untreated HER2-negative unresectable or metastatic gastric or gastroesophageal adenocarcinoma: sBLA 125554/S-091 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co. and sBLA 125514/S-143 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024
- FDA advisory committee calendar: "The Committee will discuss the existing sBLAs which were approved for patients with previously untreated unresectable or metastatic esophageal squamous cell carcinoma: sBLA 125514/S-096 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; sBLAs 125554/S-105 and S-106 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co.; and sBLA 125377/S-122 for YERVOY (ipilimumab) injection, submitted by Bristol Myers-Squibb Co." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024

### November 11, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: recurrent solid tumors.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096268): "(Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/ea022067001ex99-1_citius.htm

### November 11, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: recurrent solid tumors.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096269): "Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®)" https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea022066601ex99-1_citius.htm
- SEC Form 8-K (accession 0001213900-24-096269): "On November 11, 2024, Citius Oncology, Inc. issued a press release to announce preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096269): "(Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea022066601ex99-1_citius.htm

### December 11, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-162 (Efficacy): submission_status AP, submission_status_date 20241211, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### January 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-172 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### March 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-170 (Efficacy): submission_status AP, submission_status_date 20250319, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### April 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-174 (Efficacy): submission_status AP, submission_status_date 20250421, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### May 8, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Metastatic Esophageal Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04949256 (Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-20." https://clinicaltrials.gov/study/NCT04949256

### May 21, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." https://clinicaltrials.gov/study/NCT04895722

### May 22, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-182 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: advanced or metastatic Merkel cell carcinoma.
- First seen 2025-08-12, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-262562): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor na&iuml;ve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/d73851dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108909): "In June 2025, TuHURA announced that it had initiated its Phase 3 accelerated approval trial of IFx-2.0 as an adjunctive therapy to pembrolizumab in MCC." https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108909): "In June 2025, TuHURA initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma." https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-459326): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312526459326/hura-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-350451): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312526350451/hura-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-227245): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312526227245/hura-20260331.htm
- SEC prospectus (424B) (accession 0001193125-26-147748): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor na&iuml;ve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312526147748/d134632d424b5.htm
- SEC Form 10-K (accession 0001193125-26-134950): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/hura-20251231.htm
- SEC prospectus (424B) (accession 0001193125-25-313799): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor na&iuml;ve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312525313799/d27148d424b5.htm
- SEC Form 10-Q (accession 0001193125-25-281539): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312525281539/hura-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-108972): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000095017025108972/hura-20250630.htm
- SEC registration statement (S-1) (accession 0001193125-25-179009): "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1498382/000119312525179009/d898723ds1.htm

### June 3, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-173 (Efficacy): submission_status AP, submission_status_date 20250603, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-183 (Efficacy): submission_status AP, submission_status_date 20250606, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22
- openFDA Drugs@FDA: "BLA125514 SUPPL-180 (Efficacy): submission_status AP, submission_status_date 20250612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### June 6, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Urinary Bladder Cancer, Muscle-invasive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." https://clinicaltrials.gov/study/NCT03924895

### June 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." https://clinicaltrials.gov/study/NCT03516981

### June 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." https://clinicaltrials.gov/study/NCT04924101

### Q3 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-05-15, last confirmed 2025-05-15.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-072685): "Targeting to close the acquisition of Kineta, Inc. in Q2 2025 and initiate a Phase 2 trial of Kineta's VISTA inhibiting monoclonal antibody (mAb) in NPM1-mutated acute myeloid leukemia (AML) in Q3 2025" https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/hura-ex99_1.htm

### July 24, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-178 (Efficacy): submission_status AP, submission_status_date 20250724, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### July 29, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." https://clinicaltrials.gov/study/NCT04740307

### August 5, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." https://clinicaltrials.gov/study/NCT05007106

### August 19, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Carcinoma, Hepatocellular.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04246177 (Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-03." https://clinicaltrials.gov/study/NCT04246177

### September 23, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-04-24, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-038301): "Merck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrated Noninferior Pharmacokinetics Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial; FDA Set PDUFA Date of Sept. 23, 2025 (Read Announcement)" https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-038301): "in the U.S., the Prescription Drug User Fee Act (PDUFA) date is Sept. 23, 2025." https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_ex99-1.htm
- SEC Form 10-Q (accession 0000310158-25-000014): "- 41 - approved solid tumor indications for Keytruda and set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 23, 2025." https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-021834): "The FDA accepted for review a BLA seeking approval of MK-3475A across all previously approved solid tumor indications for Keytruda and set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 23, 2025." https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1/2.
- First seen 2025-05-14, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0002007919-25-000083): "•Initial Phase 2 data from the INBRX-106 randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with KEYTRUDA® (pembrolizumab) are expected during the fourth quarter of 2025, as well as interim data from the Phase 1/2 checkpoint inhibitor refractory or relapsed non-small cell lung cancer trial." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/exhibit99106302025.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-25-000057): "◦Interim data from the Phase 1/2 checkpoint inhibitor refractory or relapsed non-small cell lung cancer are expected during the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/exhibit99103312025.htm

### October 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Triple Negative Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." https://clinicaltrials.gov/study/NCT03036488

### October 27, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04700124 (Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04700124

### October 31, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." https://clinicaltrials.gov/study/NCT04165083

### November 5, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02625961 (Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-11-13." https://clinicaltrials.gov/study/NCT02625961

### November 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-188 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### December 23, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-12-23, last confirmed 2025-12-23.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-125418): "Announced promising preliminary results of an investigator-initiated Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea027077501ex99-1_citius.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1/2.
- First seen 2025-08-14, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108909): "Q1 2026: Anticipated topline results from Phase 1b/2a clinical trial of IFx-2.0 as an adjunctive therapy to pembrolizumab in first line treatment for MCC of unknown primary origin (MCCUP)" https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-ex99_1.htm

### January 14, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hodgkin Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02684292 (Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT02684292

### January 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04210115 (Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04210115

### January 26, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03924856 (Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-26 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT03924856

### Feb 2026: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2026-04-29, last confirmed 2026-04-29.
- SEC Form 10-Q (accession 0001628280-26-028362): "We initiated a global Phase 1/2 trial of CR-001 (the "ASCEND trial") in February 2026 and a Phase 1/2 trial of CR-003 as a monotherapy in the first quarter of 2026 in China through our partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun")." https://www.sec.gov/Archives/edgar/data/1253689/000162828026028362/cbio-20260331.htm

### February 3, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-02-03, last confirmed 2026-02-03.
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000005): "Pfizer and Astellas announced the U.S. Food and Drug Administration (FDA) approved Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy (surgery) as adjuvant treatment for adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm

### February 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Carcinoma, Renal Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04736706 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04736706

### February 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Carcinoma, Renal Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05899049 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05899049

### February 10, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-186 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### February 23, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06558799 (LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor NovoCure GmbH." https://clinicaltrials.gov/study/NCT06558799

### March 5, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2/3. Indication: Carcinoma, Squamous Cell; Skin Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06295809 (A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06295809

### March 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06036836 (Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06036836

### March 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Lung Cancer; Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06698042 (A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06698042

### April 7, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-10-30, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0000310158-25-000059): "The FDA set a PDUFA date of April 7, 2026, marking the first concurrent review of both Keytruda and Keytruda Qlex for the same novel indication." https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-103974): "Prescription Drug User Fee Act (PDUFA) Date of April 7, 2026" https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm

### April 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04895358 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-24 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04895358

### May 5, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: muscle-invasive bladder cancer.
- First seen 2026-05-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000053): "Pfizer and Astellas Pharma Inc. announced the FDA accepted for priority review a sBLA for perioperative (before and after surgery) Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as treatment for patients with muscle-invasive bladder cancer (MIBC)." https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000053): "Announced the FDA accepted and granted priority review for the supplemental Biologics License Application (sBLA) for Hympavzi to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors." https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm

### June 8, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." https://clinicaltrials.gov/study/NCT03516981?tab=results

### June 8, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04123366 (Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04123366

### June 8, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." https://clinicaltrials.gov/study/NCT04895722?tab=results

### June 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-192 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### June 23, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." https://clinicaltrials.gov/study/NCT04740307?tab=results

### June 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-187 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### June 30, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Urinary Bladder Cancer, Muscle-invasive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." https://clinicaltrials.gov/study/NCT03924895?tab=results

### July 1, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." https://clinicaltrials.gov/study/NCT04924101?tab=results

### July 10, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-194 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### August 4, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: muscle-invasive bladder cancer.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000094): "Pfizer and Astellas Pharma Inc. announced FDA approval of Padcev plus pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility." https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm

### September 28, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." https://clinicaltrials.gov/study/NCT05007106?tab=results

### Oct 2026: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2026-08-13, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001193125-26-349185): "We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026." https://www.sec.gov/Archives/edgar/data/1861123/000119312526349185/eikn-20260630.htm

### October 16, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125514 SUPPL-191 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22

### October 22, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Triple Negative Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." https://clinicaltrials.gov/study/NCT03036488?tab=results

### October 29, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." https://clinicaltrials.gov/study/NCT04165083?tab=results

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometrial Neoplasms.
- First seen 2025-08-14, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04634877
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108909): "2H 2026: Anticipated topline results from Phase 3 accelerated approval trial" https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-ex99_1.htm

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometrial Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04634877

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Urinary Bladder Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04241185

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05609968

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05609968

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Urinary Bladder Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04241185

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hodgkin Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT03407144

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hodgkin Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT03407144

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasm Malignant.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04976634 (Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04976634

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neoplasm Malignant.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04976634 (Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04976634

### mid-2027: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-04-29, last confirmed 2026-04-29.
- SEC Form 10-Q (accession 0001628280-26-028362): "We anticipate initiation of a CR-002 monotherapy clinical trial in 2026 as well as the first ADC combination trial with CR-001 with initial data anticipated in mid-2027 (second or third quarter)." https://www.sec.gov/Archives/edgar/data/1253689/000162828026028362/cbio-20260331.htm

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Advanced Cancer; Anal Carcinoma; Anal Cancer.
- First seen 2026-04-01, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02628067 (Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT02628067
- Press release filed with the SEC (EX-99) (accession 0001193125-26-227204): "2H 2027: Anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first-line treatment for advanced or metastatic MCC" https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/hura-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-135766): "2H 2027: Anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic MCC" https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/hura-ex99_1.htm

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04380636 (Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04380636

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometrial Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05173987 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05173987

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Advanced Cancer; Anal Carcinoma; Anal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02628067 (Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT02628067

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04380636 (Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04380636

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometrial Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05173987 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05173987

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06312176

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06312176

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04624204

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04624204

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06170788

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06307431 (A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06307431

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06345729

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06307431 (A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06307431

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06345729

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06170788

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: High-risk Non-muscle Invasive Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT03711032

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Malignant Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06961006 (A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06961006

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Malignant Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06961006 (A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06961006

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: High-risk Non-muscle Invasive Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT03711032

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colorectal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05239741

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Malignant Neoplam; Advanced Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07793942 (A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07793942

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colorectal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05239741

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Malignant Neoplam; Advanced Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07793942 (A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07793942

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Malignant Pleural Mesothelioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05425576 (OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Oncotelic Inc.." https://clinicaltrials.gov/study/NCT05425576

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Malignant Pleural Mesothelioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05425576 (OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Oncotelic Inc.." https://clinicaltrials.gov/study/NCT05425576

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer; NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06422143

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer; NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06422143

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Squamous Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221474 (A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07221474

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Squamous Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221474 (A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07221474

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05933577

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05933577

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Malignant Neoplasm.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07252739 (KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07252739

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Malignant Neoplasm.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07252739 (KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07252739

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Neoplasms; Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06797635 (Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06797635

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Neoplasms; Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06797635 (Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06797635

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Triple Negative Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06841354

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Triple Negative Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06841354

### Jun to Sep 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06077760

### June 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06077760

## Same indication

- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib) (LLY)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Gemzar (gemcitabine)](https://sec-api.dev/pdufa/gemcitabine) (JNJ)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [TAR-200](https://sec-api.dev/pdufa/tar-200) (JNJ)
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib) (PFE)
- [Vepugratinib](https://sec-api.dev/pdufa/vepugratinib) (LLY)
- [(z)-endoxifen](https://sec-api.dev/pdufa/z-endoxifen) (ATOS)

Calendar months: [September 2025](https://sec-api.dev/fda-calendar/2025-09), [April 2026](https://sec-api.dev/fda-calendar/2026-04), [November 2026](https://sec-api.dev/fda-calendar/2026-11), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [May 2027](https://sec-api.dev/fda-calendar/2027-05), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [January 2028](https://sec-api.dev/fda-calendar/2028-01), [July 2028](https://sec-api.dev/fda-calendar/2028-07), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pembrolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KEYTRUDA® (pembrolizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pembrolizumab

```bibtex
@misc{secapidev_pdufa_pembrolizumab_20261116,
  title        = {KEYTRUDA® (pembrolizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pembrolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pembrolizumab_20261116","title":"KEYTRUDA® (pembrolizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pembrolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
